ArticleJournal of translational medicine2026
Targeting osteopontin with gold nanoparticles for enhanced molecular imaging in Kawasaki disease: in-depth mechanistic study of STAT3 signaling in Col1 regulation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundKawasaki disease (KD) is a primary cause of acquired heart disease in children, often leading to significant complications like coronary artery lesions and vasculitis. Despite the administration of standard treatments, 10–20% of patients remain unresponsive, emphasizing the necessity for the development of improved diagnostic and treatment modalities. Given the limitations of conventional imaging techniques, this study investigates the potential of molecular imaging using targeted nanoparticles. Here, the role of osteopontin (OPN) in macrophage-dependent vascular inflammation and cardiovascular pathology is examined, as it may be crucial in the context of KD.
methodsGold nanoparticles (Au NPs) were synthesized through an amidation reaction to create OPN-Au NPs and mIgG-Au NPs. These were characterized using transmission electron microscopy and UV-vis spectra data, and their cytotoxicity was evaluated via cell viability and flow cytometry. The targeting efficacy of OPN-Au NPs was tested in vivo using CT imaging in a Kawasaki disease animal model. Furthermore, the role of BMDM-derived OPN in primary cardiac fibroblast activation was investigated through gene knockout and molecular mechanism analysis. The action mechanism of STAT3 on the epigenetic regulation of Col1 induced by OPN was studied using dual-luciferase reporter assays and ChIP-PCR.
resultsThe Au NPs exhibited favorable optical properties and low cytotoxicity. In vivo CT imaging demonstrated the capacity of these NPs to enhance the imaging of coronary artery lesions. Furthermore, BMDM-derived OPN was demonstrated to regulate fibroblast function via STAT3 signaling. Dual-luciferase reporter assays and ChIP-PCR revealed that OPN-mediated STAT3 regulates the transcriptional expression of Col1 at the epigenetic level.
conclusionThe findings indicate the potential of molecular imaging using Au NPs for the early detection and diagnosis of KD. Of note, the research demonstrates the role of OPN in modulating fibroblast activation through STAT3 signaling and its influence on the epigenetic regulation of Col1. This provides critical insights into the immune cell-fibroblast interaction in cardiovascular diseases, offering prospects for more targeted and effective diagnostic and therapeutic strategies for KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.